The principal objectives in the treatment of acromegaly are: (1) to halt or reverse tumour growth, thereby controlling symptoms of compression, (2) to improve symptoms and comorbidities resulting from the excessive plasma concentrations of GH and IGF-1 and (3) to eliminate the increased mortality rate associated with the disease by effectively reducing GH and by normalizing IGF-1 concentrations.5–7. The gene discussed is IGF1; the disease is acromegaly.